The MD Magazine Atherosclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

PCSK9 Inhibitor Dramatically Reduces Cholesterol in Patients with Familial Hypercholesterolemia
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)— approved in July in the US — lowered cholesterol in patients with familial hypercholesterolemia to levels “unreachable with statins” researchers said at the European Society of Cardiology meeting in London, UK.
While PCSK9 inhibitors have been shown to help patients lower their cholesterol levels, there are still questions about potential side effects as well as when and how the medication will be made affordable and available to patients.
It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.
The US Food and Drug Administration last night announced it has approved evolocumab (Repatha/Amgen), an injectable drug for some patients who are unable to get their LDL cholesterol under control. Statins are a cheaper and generally effective treatment, but the new class of drugs is expected to help people who cannot tolerate them, for whom they do not work, and for people with heterozygous familial hypercholesterolemia.
High levels of noncalcified coronary plaque and an increased risk for heart attack is linked to poor HDL-cholesterol efflux capacity (CEC) in patients with psoriasis.
Cardiovascular disease is the most common comorbidity in patients with rheumatoid arthritis (RA) and the reason behind it may have finally been identified.

Most Popular

$vacMongoViewPlus$ $vAR$